MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
LYON, France--(BUSINESS WIRE)--Regulatory News:
The first months of 2025 have marked a pivotal moment for MaaT Pharma with the positive results from our Phase 3 trial of MaaT013, our lead asset.
Share
MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provided a business update and reported its cash position as of March 31, 2025.
'The first months of 2025 have marked a pivotal moment for MaaT Pharma with the positive results from our Phase 3 trial of MaaT013, our lead asset. This milestone enables us to advance toward a Market Authorization submission in Europe and reflects over a decade of dedication and close collaboration with physicians. We are deeply grateful for the trust and participation of patients, whose support has been essential in achieving this progress,' said Hervé Affagard, CEO and co-founder of MaaT Pharma. 'We are also making strong progress across our pipeline, with encouraging outcomes for MaaT033 and MaaT034. Additionally, by extending our cash runway to October 2025, we are well-positioned to deliver on our upcoming value-creating milestones.'
Pipeline highlights
In Hemato-Oncology
Acute Graft-versus-Host Disease (aGvHD) – MaaT013
In January 2025, the Company announced positive topline results from the pivotal Phase 3 ARES Study evaluating MaaT013 in aGvHD. The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment of aGvHD with gastrointestinal involvement (GI-aGvHD) consistent with previously communicated EAP results. The Company anticipates MAA submission in Europe in June 2025.
In March 2025, the Company received positive opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013, a key milestone achieved towards the MAA submission to the EMA.
In March 2025, the Company received a positive outcome from the final DSMB meeting on ARES Phase 3 trial, confirming the remarkable efficacy results and positive risk/benefit profile of MaaT013 in third-line aGvHD.
Earlier this year, the Company announced its intent to partner the distribution of MaaT013 in Europe, while retaining MaaT013 rights in the U.S.
Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) - MaaT033
In January 2025, the Company announced that the DSMB completed its second safety assessment of the Phase 2b trial PHOEBUS and recommended continuation of the trial without modification.
In April 2025, the Company announced the positive outcome of a key DSMB safety interim analysis for the Phase 2b trial PHOEBUS. As a result of their unblinded analysis, the DSMB recommended the trial to proceed as planned, showing no excessive mortality related to MaaT033 as of today. This additional positive outcome further reinforces MaaT033's safety profile and supports MaaT033's integration in the allo-HSCT setting without significant risks of severe adverse events.
In Immuno-Oncology
MaaT034 - Next-generation drug candidates with co-cultured technology (MET-C platform)
In April 2025, MaaT Pharma presented promising preclinical data for MaaT034 at the American Association for Cancer Research (AACR) Annual Meeting 2025, demonstrating strong anti-tumor efficacy and immune activation in germ-free mice.
MaaT013– Proof-of-Concept trials with donor derived drugs (MET-N platform)
MaaT013 is currently being evaluated in a Phase 2a randomized clinical trial (NCT04988841) (PICASSO) sponsored by AP-HP and in collaboration with INRAE and Institut Gustave Roussy, in combination with immune checkpoint inhibitors (ICI), ipilimumab (Yervoy®) and nivolumab (Opdivo®), in metastatic melanoma patients. The Company provided its MaaT013 drug candidate and placebo and contributes to the microbiome profiling of patients using its proprietary gutPrint® AI research engine, while the trial investigator sponsor handled recruitment, treatment and oversee data collection and analysis. Data readout is expected in H2 2025.
In Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis (ALS) - MaaT033
In May 2025, MaaT Pharma announced positive final Phase 1b results for MaaT033 in ALS, showing a favorable safety and tolerability profile supported by biomarker and microbiome analyses. Rapid and sustained microbial engraftment was observed, along with a slower rate of disease progression (ALSFRS-R slope to be interpreted with caution. The Company is seeking a partner to further advance clinical evaluation in ALS.
Corporate update
In April 2025, the Company announced the initiation of coverage of its stock by H.C. Wainwright & Co. With a research report named ' In With the Gut and Out With the Bad in GvHD; Initiating at Buy With a €21 PT', H.C. Wainwright & Co initiated a Buy recommendation and a Target Price of €21.
Cash position 1
As of March 31, 2025, total cash and cash equivalents were EUR 24.4 million, as compared to EUR 20.2 million as of December 31, 2024. The net increase in cash position of EUR 4.2 million during the first quarter of 2025 includes the capital increase of €13 million supported by historical shareholders, while investment in R&D activities continued across the pipeline. The Company believes it has sufficient cash to cover its current needs and planned development programs into October 2025 and is exploring several options to further extend its cash horizon.
Revenues in Q1 2025 1
MaaT Pharma reported revenues of EUR 1.1 million for the first quarter of 2025 compared with EUR 0.8 million for the same period of 2024 representing a constant growth, quarter to quarter, year to year.
Upcoming financial communications*
June 20, 2025: Annual General Meeting
September 16, 2025: Publication of H1 2025 results
November 4, 2025: Publication of revenues & cash for Q3 2025
*Indicative calendar that may be subject to change.
Upcoming investor and business conferences participation
June 12-15 – European Hematology Association (EHA) Congress, Milan
June 16-19, 2025 – Bio International Convention, Boston, MA
June 18-19, 2025 – Portzamparc Conference Mid & Small Caps 2025, Paris
September 25, 2025 – KBC Healthcare Conference, Brussels
---
About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
1 unaudited financial results
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 minutes ago
- Associated Press
DEADLINE ALERT for CAR, NSSC, LPRO, CIVI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected]. Avis Budget Group, Inc. (NASDAQ: CAR ) Class Period: February 16, 2024 – February 10, 2025 Lead Plaintiff Deadline: June 24, 2025 The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Avis crafted and implemented a plan to significantly accelerate its fleet rotation in the fourth quarter of 2024; (2) the foregoing acceleration shortened the useful life of the majority of the Company's vehicles in the Americas segment, thereby reducing their recoverable value; (3) as a result, Avis would be forced to recognize billions of dollars in impairment charges and incur substantial losses; (4) all the foregoing was likely to, and did, have a significant negative impact on the Company's financial results; (5) accordingly, Avis's financial and/or business prospects were overstated; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Napco Security Technologies, Inc. (NASDAQ: NSSC ) Class Period: February 5, 2024 – February 3, 2025 Lead Plaintiff Deadline: June 24, 2025 The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company was simply not equipped to adequately forecast demand for its products or otherwise minimized the impact of potential demand fluctuations to continue to promote its lofty margin projections which relied upon continually increased sales volumes; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Open Lending Corporation (NASDAQ: LPRO ) Class Period: February 24, 2022 – March 31, 2025 Lead Plaintiff Deadline: June 30, 2025 The complaint alleges that throughout the Class Period the Defendants: (1) misrepresented the capabilities of the Company's risk-based pricing models; (2) issued materially misleading statements regarding the Company's profit share revenue; (3) failed to disclose the Company's 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; (4) misrepresented the underperformance of the Company's 2023 and 2024 vintage loans; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Civitas Resources, Inc. (NYSE: CIVI ) Class Period: February 27, 2024 – February 24, 2025 Lead Plaintiff Deadline: July 1, 2025 The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Civitas was highly likely to significantly reduce its oil production in 2025 as a result of, inter alia, declines following the production peak at the DJ Basin in the fourth quarter of 2024 and a low TIL count at the end of 2024; (2) increasing its oil production would require the Company to acquire additional acreage and development locations, thereby incurring significant debt and causing the Company to sell corporate assets to offset its acquisition costs; (3) the Company's financial condition would require it to implement disruptive cost reduction measures including a significant workforce reduction; (4) accordingly, Civitas's business and/or financial prospects, as well as its operational capabilities, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to [email protected], or visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 888-638-4847 [email protected]
Yahoo
2 hours ago
- Yahoo
Lottery.com Regains Nasdaq Compliance as Stock Trading Activity Soars
FORT WORTH, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Inc. (NASDAQ: LTRY; LTRYW) (' or 'the Company') received formal notice (the 'Notice') from The Nasdaq Stock Market LLC ('Nasdaq') confirming that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 (the 'Rule'). The Company met this requirement by maintaining a closing bid price of $1.00 or higher for twenty consecutive business days from May 21 through June 18, 2025. Nasdaq has officially closed the matter. This confirmation marks more than just a technical compliance milestone—it underscores the momentum has built in recent weeks. In the 20-day period leading up to regaining compliance with Rule, stock experienced exceptional market activity, with daily trading volumes frequently exceeding 30 million shares. On May 27, 2025, recorded trading volume of more than 166 million shares, ranking among the most actively traded stocks on Nasdaq that day.'This isn't just a moment of compliance—this is a true turning point. The level of engagement from the markets over the last 20 days, combined with our recent momentum, demonstrates that our turnaround is real, visible and gaining traction. We are entering our next chapter with a key compliance determination from Nasdaq, a reinforced leadership team and a Company that is starting to fire on all cylinders. Our investors have seen the difference—and the volume speaks for itself.' As part of this renewed momentum, the Company recently appointed actor and media executive Tamer Hassan as President of Studios, further strengthening its media and entertainment vertical. The Company also continues to work with legal advisors, including Paul Hastings LLP, in its investigation into suspected illegal short selling and is prepared to take legal action against any parties found to have manipulated its stock. About The Inc. (NASDAQ: LTRY, LTRYW) family of brands — including Tinbu and WinTogether, comprise a unified ecosystem that integrates gaming, entertainment, and sports. Follow the Company on X, Instagram and Facebook. Forward-Looking StatementsThis press release contains statements that constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words 'could,' 'should,' 'will,' 'may,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'project,' 'initiatives,' 'continue,' the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, expectations related to the investigation of short selling or potential naked short selling, including the Company's analysis, its ability to take appropriate corrective action, or any potential investigations by regulators; any future findings from ongoing review of the Company's internal accounting controls; additional examination of the preliminary conclusions of such review; the Company's ability to secure additional capital resources; the Company's ability to continue as a going concern; the Company's ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq; the Company's ability to regain compliance with the Bid Price Requirement; the Company's ability to regain compliance with Nasdaq Listing Rules; the Company's ability to become current with its SEC reports; and those additional risks and uncertainties discussed under the heading 'Risk Factors' in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. CONTACT: For more information, please visit or contact our media relations team at press@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
2 hours ago
- Business Wire
Tidewater Announces Offering of $650 Million of Senior Notes Due 2030
HOUSTON--(BUSINESS WIRE)--Tidewater Inc. (NYSE: TDW) ('Tidewater' or 'the Company') today announced that it has commenced a private offering (the 'Offering') of $650 million in aggregate principal amount of unsecured senior notes due 2030 (the '2030 Notes'). The Company expects to use the net proceeds from the Offering, together with cash on hand, (i) to repay in full the Company's existing senior secured term loan, (ii) to fund the redemption (the 'Redemption') of both the Company's outstanding 8.50% Senior Secured Bonds due 2026 (the '2026 Bonds') and its outstanding 10.375% Senior Unsecured Bonds due 2028 (the '2028 Bonds') and (iii) to pay the premiums, accrued interest, fees and expenses related to the term loan payoff, Redemption and the issuance of the 2030 Notes. The 2030 Notes will be senior unsecured obligations of the Company and will be guaranteed on a senior unsecured basis by certain of the Company's U.S. subsidiaries. The 2030 Notes are being offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'), and to persons outside the United States only in compliance with Regulation S under the Securities Act. The 2030 Notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release does not and shall not constitute an offer to sell nor a solicitation of an offer to buy the 2030 Notes, nor shall there be any offer, solicitation or sale of the 2030 Notes in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The Offering may be made only by means of an offering memorandum. This news release does not constitute a notice of redemption for the 2026 Bonds or the 2028 Bonds. About Tidewater Tidewater owns and operates the largest fleet of offshore support vessels in the industry, with 65 years of experience supporting offshore energy exploration, production and offshore wind activities worldwide. Cautionary Statement This news release contains 'forward-looking statements' within the meaning of the U.S. federal securities laws, including those relating to the Offering of the 2030 Notes and the expected use of proceeds therefrom. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, possibly materially, from expectations or estimates reflected in such forward-looking statements, including, among others: the ability to complete the Offering on favorable terms, if at all, and general market conditions that might affect the Offering. Additional risks and uncertainties are detailed in the Company's most recent filings with the SEC, including under the captions 'Forward-Looking Statements' and 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Statements in this news release are made as of the date hereof, and the Company disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
